AZ to rework ongoing immuno-oncology trials to “enhance options”

pharmafile | January 17, 2017 | News story | Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, non-small cell lung cancer 

Due to the “strong efficacy” shown by its durvalumab as a treatment for non-small cell lung cancer (NSCLC), AstraZeneca has announced it is to reengineer its clinical trials into the drug in order to “enhance [its] options”, according to company CMO Sean Bohen.

The amendments to its Mystic trial and other related trials investigating durvalumab intend to help explore the firm’s options in first-line NSCLC treatment for a combination of immune-oncology treatments and monotherapy. The Mystic trial was originally designed to evaluate progression-free survival of the drug as a monotherapy and in combination with tremelimumab in patients with PDL1-expressing tumours versus standard-of-care chemotherapy; now redesigned, the trial will also assess overall survival.

First data from the Mystic trial will be released midway through this year, with final results expected sometime in 2018.

Aside from the Mystic trial, the firm is looking to reinforce its regulatory submission of durvalumab in combination with tremelimumab as a first-line NSCLC treatment in China by expanding its Neptune trial in the region with local patients.

Matt Fellows

Related Content

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …


Japan approves AstraZeneca’s Soliris for paediatric patients with gMG

AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris …

Latest content